The company is discontinuing the Phase 1 ELiPSE-1 trial due to insufficient data for its late-stage NHL program, while expanding the CALiPSO-1 trial in the U.S. and Europe. The company is also ...

“We have made the strategic decision to discontinue the Phase 1 ELiPSE-1 trial early, and we thank the patients, providers and caregivers for their support and participation. We believe CNTY-101 ...